Article

Daily Medication Pearl: Fluticasone Furoate and Vilanterol (Breo Ellipta)

Breo Ellipta is indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Medication Pearl of the Day: Fluticasone Furoate and Vilanterol (Breo Ellipta)

Indication: Breo Ellipta is a combination of fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist, indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Insight:

  • Dosing: Inhalation of Breo Ellipta 100/25 once daily.
  • Dosage forms: Inhaler containing 2 foil blister strips of powder formulation for oral inhalation. One strip contains fluticasone furoate 100 or 200 mcg per blister and the other contains vilanterol 25 mcg per blister.
  • Adverse events: Nasopharyngitis, upper respiratory tract infection, headache, oral candidiasis, back pain, pneumonia, bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, hypertension, influenza, pharyngitis, and pyrexia.
  • Mechanism of action: Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Vilanterol is a long-acting Beta agonist.
  • Manufacturer: GlaxoSmithKline

Sources:

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com